Tag: Tocilizumab

1. Compared to usual care, fewer patients in the tocilizumab group died within 28 days of randomization. 2. Patients allocated tocilizumab were more likely to be discharged from the hospital within 28 days. Evidence Rating Level: 1 (Excellent) Study Rundown: Hypoxic respiratory failure in patients with COVID-19 is associated with systemic inflammation, alveolar damage,...
1. Compared to usual care, fewer patients in the tocilizumab group died within 28 days of randomization. 2. Patients allocated tocilizumab were more likely to be discharged from the hospital within 28 days. Evidence Rating Level: 1 (Excellent) Study Rundown: Hypoxic respiratory failure in patients with COVID-19 is associated with systemic inflammation,...
1. Tocilizumab reduced the need for mechanical ventilation and lowered death outcomes in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2. Treatment with tocilizumab did not improve survival among patients. Evidence Rating Level: 1 (Excellent) Study Rundown: Cases pertaining to the coronavirus disease 2019 (Covid-19) have led to severe clinical manifestations...
1. Tocilizumab reduced the need for mechanical ventilation and lowered death outcomes in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 2. Treatment with tocilizumab did not improve survival among patients. Evidence Rating Level: 1 (Excellent) Study Rundown: Cases pertaining to the coronavirus disease 2019 (Covid-19) have led to severe...
1. Treatment with tocilizumab and sarilumab increased the number of days without respiratory or cardiovascular organ support in patients with COVID-19. 2. Interleukin-6 receptor antagonists improved in-hospital survival for patients diagnosed with COVID-19 and receiving organ support in the ICU. Evidence Rating Level: 1 (Excellent) Study Rundown: Thus far, only glucocorticoids have...
1. Among patients categorized as B-cell poor group via RNA sequencing, tocilizumab had a significantly higher response rate than rituximab. 2. Likelihood of adverse events and serious adverse events were comparable between both treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Rheumatoid arthritis is a chronic autoimmune condition with considerable morbidity and mortality...
1. Tocilizumab was not superior to standard care after 15 days, for COVID-19 patients in serious condition. 2. Patients given tocilizumab had higher rates of mortality and adverse events, but shorter hospital stays compared to the standard care group. Evidence Rating Level: 1 (Excellent) Study rundown: The COVID-19 pandemic has resulted in nearly 100...
1. Among patients categorized as B-cell poor group via RNA sequencing, tocilizumab had a significantly higher response rate than rituximab. 2. Likelihood of adverse events and serious adverse events were comparable between both treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Rheumatoid arthritis is a chronic autoimmune condition with considerable morbidity...
1. Hydroxychloroquine use in hospitalized and tocilizumab use in ICU lab-positive COVID-19 patients were not been associated with decreased death. Evidence Rating Level: 2 (Good) There is ongoing research into evaluating potential treatment options for COVID-19. Despite conflicting evidence, hydroxychloroquine (with or without azithromycin) remains a popular option, while  preliminary results...
Tumour necrosis factor (TNF) alpha inhibitors have greatly improved disease control and quality of life in patients affected by rheumatoid arthritis; however, up to one third of patients fail to respond to these agents. Alternative non-TNF targeted biologics have also emerged, including rituximab, abatacept and tocilizumab. In this prospective...